Search results
Results from the WOW.Com Content Network
Trapeziometacarpal osteoarthritis (TMC OA) is, also known as osteoarthritis at the base of the thumb, thumb carpometacarpal osteoarthritis, basilar (or basal) joint arthritis, or as rhizarthrosis. [ 3 ] [ 1 ] [ 2 ] This joint is formed by the trapezium bone of the wrist and the metacarpal bone of the thumb.
The choice of antiarthritic medication is often determined by the nature of arthritis, the severity of symptoms as well as other factors, such as the tolerability of side effects. A dorsal view of the hand, revealed swelling of the finger joints, indicative of an underlying inflammatory process at the proximal interphalangeal joints
The procedure was considered a major breakthrough in the medical field at the time. However, it is now considered an almost standard operation. The first successful surgery of this kind was conducted on 21 December 1992, in New York City, US. This surgical option is reserved for patients with advanced arthritis or with a hand deformity.
Ligament anchoring procedures can restore ligament-bone connections via pins, which can be relied on for treatment of a damaged ulnar collateral ligament in gamekeeper's thumb. [4] On a case-to-case basis, interphalangeal joint deformities may also be surgically treated by pins, in order to correct their position in the digit.
Symptoms are pain and tenderness at the radial side of the wrist, fullness or thickening over the thumb side of the wrist, painful radial abduction of the thumb, and difficulty gripping with the affected side of the hand. [2] Pain is made worse by movement of the thumb and wrist, and may radiate to the thumb or the forearm. [2]
Combinations of DMARDs are often used, because each drug in the combination can be used in a smaller dose than if it were given alone, thus reducing the risk of side effects. [citation needed] Many patients receive an NSAID and at least one DMARD, sometimes with low-dose oral glucocorticoids. If disease remission is observed, regular NSAIDs or ...
Rooney is the lead author of a new study reporting that certain changes to the gut microbiome may be linked to the development of rheumatoid arthritis, potentially opening up a new pathway for ...
Rofecoxib was approved by the FDA to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, acute pain conditions, migraine, and dysmenorrhea. When it was marketed, it gained widespread acceptance among physicians treating patients with arthritis and other conditions causing chronic or acute pain.